Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and
determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Although a cornerstone in the treatment of heart failure, angiotensin-converting enzyme
inhibitors are under-used, partly due to side effects. If proven at least similarly efficacious to …

Abstract Background The Valsartan Heart Failure Trial (Val‐HeFT) is the first large‐scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Background—ACE inhibitors may not adequately suppress deleterious levels of angiotensin
II in patients with heart failure. An angiotensin receptor blocker added to an ACE inhibitor …

Background: To investigate the role of persistent angiotensin activity despite
angiotensinconverting enzyme inhibitor therapy in the progression of heart failure, the …

Abstract Abstract Valsartan (Diovan®) is an oral angiotensin II-receptor antagonist with
specificity for the angiotensin II type 1 receptor subtype. It demonstrates antihypertensive …